作者: 輕率看法 時(shí)間: 2025-3-21 22:39 作者: Cocker 時(shí)間: 2025-3-22 02:09 作者: 高興一回 時(shí)間: 2025-3-22 06:41
https://doi.org/10.1007/978-3-662-30424-2these systems to meet demanding clinical needs, we then examine the interaction of biolistic devices with the skin, focusing on the mechanical interactions of ballistic impact and cell death, and finally we discuss the current clinical outcomes of one key application of engineered delivery devices –作者: lethargy 時(shí)間: 2025-3-22 12:27
https://doi.org/10.1007/978-3-662-30424-2IUDs/IUSs and framed LNG-IUS are the beginning of a series of innovative developments in this field. New compounds, such as progesterone antagonists and selective progesterone receptor modulators (SPRMs), could be incorporated into polymeric drug delivery platforms for use in the uterus, cervix, or 作者: 繁忙 時(shí)間: 2025-3-22 15:02
https://doi.org/10.1007/978-3-662-30424-2fore be addressed. Growth factor release from scaffolds for tissue regeneration offers a new approach of incorporating high-molecular-weight bioactive agents which are very sensitive to process conditions and preserve their activity during the preparation stage. The drug-eluting medical implants are作者: 繁忙 時(shí)間: 2025-3-22 20:00
Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example specific ligands to the surface of pharmaceutical carriers to recognize and bind pathological cells. Here, we will consider and discuss these two targeting approaches using tumor targeting as an example.作者: Endemic 時(shí)間: 2025-3-22 22:25
Lipid Nanoparticles: Effect on Bioavailability and Pharmacokinetic Changes downwards depending on the therapeutic requirement. Definitions of the morphological characteristics, surface properties, and polymorphic structures will also be given, emphasizing their influence on the incorporation parameters of the API, such as yield of production, loading capacity, and encapsu作者: 要素 時(shí)間: 2025-3-23 02:09 作者: 喪失 時(shí)間: 2025-3-23 06:49 作者: oracle 時(shí)間: 2025-3-23 09:46
Intrauterine Drug Delivery for Contraception and Gynaecological Treatment: Novel ApproachesIUDs/IUSs and framed LNG-IUS are the beginning of a series of innovative developments in this field. New compounds, such as progesterone antagonists and selective progesterone receptor modulators (SPRMs), could be incorporated into polymeric drug delivery platforms for use in the uterus, cervix, or 作者: Meager 時(shí)間: 2025-3-23 14:23 作者: 我正派 時(shí)間: 2025-3-23 20:08
Book 2010overing today’s options for specific carrier systems allowing successful drug treatment at various sites of the body difficult to address and allowing to increase the benefit-risk-ratio to the optimum possible..作者: 創(chuàng)新 時(shí)間: 2025-3-23 22:56
0171-2004 rious modern approaches to drug targeting covering today’s options for specific carrier systems allowing successful drug treatment at various sites of the body difficult to address and allowing to increase the benefit-risk-ratio to the optimum possible..978-3-642-26290-6978-3-642-00477-3Series ISSN 0171-2004 Series E-ISSN 1865-0325 作者: LINES 時(shí)間: 2025-3-24 06:06 作者: conjunctiva 時(shí)間: 2025-3-24 06:30
Mucoadhesive Drug Delivery Systemsucus, the different mucoadhesion theories and binding types between mucus and mucoadhesives, mucoadhesion tests and factors influencing mucoadhesion are introduced. Various mucoadhesive polymers are also described and an overview of various mucoadhesive delivery systems is provided.作者: 谷物 時(shí)間: 2025-3-24 14:13 作者: 壓倒 時(shí)間: 2025-3-24 15:45
https://doi.org/10.1007/978-3-662-30424-2ssue. The construction and production of retrovirus, lentivirus, and AAV vectors are covered. The focus is on production methods suitable for biopharmaceutical upscaling and for downstream processing. Quality control measures and biological safety considerations for the use of vectors in clinical trials are discussed.作者: Landlocked 時(shí)間: 2025-3-24 20:42 作者: Inoperable 時(shí)間: 2025-3-25 02:30 作者: fodlder 時(shí)間: 2025-3-25 04:15 作者: 詞根詞綴法 時(shí)間: 2025-3-25 10:12
Improving Oral Deliveryion, degradation and permeability can be adjusted to improve oral delivery. Future developments will focus on further improvement in patient compliance as well as the feasibility of administering biotech drugs via the oral route.作者: Diatribe 時(shí)間: 2025-3-25 12:40
0171-2004 ule is seen as an active pharmaceutical ingredient and not as a complex mixture of chemical entities of a well defined structure. Today, we are becoming more and more aware of the fact that delivery of the active compound to the target site is a key. The present volume gives a topical overview on va作者: 粗糙濫制 時(shí)間: 2025-3-25 16:00
https://doi.org/10.1007/978-3-662-30424-2systems. An additional focus is on new polymers (dendrimers, hyperbranched polymers), considering their chemical versatility, uniqueness, and future implications. Problems associated with controlled drug release systems are also highlighted. Finally, applications of FDA-approved polymers used for oral drug delivery systems are outlined.作者: 贊成你 時(shí)間: 2025-3-25 21:44
https://doi.org/10.1007/978-3-662-30424-2ucus, the different mucoadhesion theories and binding types between mucus and mucoadhesives, mucoadhesion tests and factors influencing mucoadhesion are introduced. Various mucoadhesive polymers are also described and an overview of various mucoadhesive delivery systems is provided.作者: Amplify 時(shí)間: 2025-3-26 01:23 作者: Debark 時(shí)間: 2025-3-26 05:12
https://doi.org/10.1007/978-3-662-30424-2f strategies which aim to enhance brain uptake of beneficial pharmaceutical compounds. The different strategies discussed in this review aim to modulate blood–brain barrier function or to bypass constituents of the blood–brain barrier.作者: 禁令 時(shí)間: 2025-3-26 10:33 作者: evaculate 時(shí)間: 2025-3-26 15:52
Transdermal Drug Deliveryntophoresis, have reached true maturity. The “l(fā)ocal”, subcutaneous delivery of drugs (for example, to underlying muscle and other tissues) is gaining increasing acceptance, and new opportunities in this under-subscribed area may be envisaged.作者: 嘲笑 時(shí)間: 2025-3-26 19:29
Targeting the Brain – Surmounting or Bypassing the Blood–Brain Barrierf strategies which aim to enhance brain uptake of beneficial pharmaceutical compounds. The different strategies discussed in this review aim to modulate blood–brain barrier function or to bypass constituents of the blood–brain barrier.作者: Monocle 時(shí)間: 2025-3-26 23:31 作者: Ledger 時(shí)間: 2025-3-27 02:54 作者: Conserve 時(shí)間: 2025-3-27 07:37 作者: Entrancing 時(shí)間: 2025-3-27 13:21
Handbook of Experimental Pharmacologyhttp://image.papertrans.cn/e/image/283035.jpg作者: regale 時(shí)間: 2025-3-27 16:04
https://doi.org/10.1007/978-3-662-30424-2The book chapter “Biosensing and Drug Delivery at the Microscale: Novel Devices for a Controlled and Responsive Drug Delivery” published in the . vol. 197: . has been retracted. For further details see Erratum. 作者: peptic-ulcer 時(shí)間: 2025-3-27 21:41
Biosensing and Drug Delivery at the MicroscaleThe book chapter “Biosensing and Drug Delivery at the Microscale: Novel Devices for a Controlled and Responsive Drug Delivery” published in the . vol. 197: . has been retracted. For further details see Erratum. 作者: Embolic-Stroke 時(shí)間: 2025-3-27 22:41 作者: BAIT 時(shí)間: 2025-3-28 03:41
https://doi.org/10.1007/978-3-642-00477-3Biosensing; Drug Delivery; Drug-eluting implants; Nanocarriers; Targeted therapy; clinical application作者: 冰雹 時(shí)間: 2025-3-28 09:08 作者: fastness 時(shí)間: 2025-3-28 13:41 作者: 貞潔 時(shí)間: 2025-3-28 16:12 作者: eustachian-tube 時(shí)間: 2025-3-28 20:27
https://doi.org/10.1007/978-3-662-30424-2including therapeutic requirements and patient compliance. In this regard, several achievements have been reported with colloidal carriers, in particular with lipid nanoparticles, due to their unique physicochemical properties. For several years these carriers have been showing potential success for作者: Landlocked 時(shí)間: 2025-3-28 23:09 作者: 來(lái)就得意 時(shí)間: 2025-3-29 04:17 作者: 借喻 時(shí)間: 2025-3-29 10:47 作者: EXCEL 時(shí)間: 2025-3-29 15:06
https://doi.org/10.1007/978-3-662-30424-2 drug delivery abilities. Pharmaceutical polymers, chemical structure, and properties are discussed for their applications in controlled drug release systems. An additional focus is on new polymers (dendrimers, hyperbranched polymers), considering their chemical versatility, uniqueness, and future i作者: Fretful 時(shí)間: 2025-3-29 17:35 作者: ungainly 時(shí)間: 2025-3-29 21:38
https://doi.org/10.1007/978-3-662-30424-2nd treatment of gynaecological conditions, improvements to birth control methods, and higher levels of safety, user acceptability, compliance, and quality of life for women. The development of frameless intrauterine systems is such an attempt to improve on the performance and acceptability of establ作者: cortex 時(shí)間: 2025-3-30 01:45
https://doi.org/10.1007/978-3-662-30424-2chieved by controlled release of active pharmaceutical ingredients (API) into the surrounding tissue. In this chapter we focus on three types of drug-eluting devices: drug-eluting vascular stents, drug-eluting wound dressings and protein-eluting scaffolds for tissue regeneration, thus describing bot作者: aspect 時(shí)間: 2025-3-30 05:56
https://doi.org/10.1007/978-3-662-30424-2he pharmaceutical industry and healthcare systems. Considering biopharmaceutical issues such as physicochemical requirements of the drug and physiological conditions, however, oral delivery is one of the most challenging routes. Recognising solubility, permeability and residence time in the gastroin作者: Hemiparesis 時(shí)間: 2025-3-30 09:02
https://doi.org/10.1007/978-3-662-30424-2eld has been observed with many commercial successes; importantly, a new chemical entity was recently developed and approved for transdermal administration without having first been given as an injectable or oral dosage form. The progress achieved has been based on the clearer understanding of skin 作者: 不愿 時(shí)間: 2025-3-30 16:27
https://doi.org/10.1007/978-3-662-30424-2utics. Effective extrusion from the brain by transporters is a frequent reason for the pharmaceutical industry to exclude novel compounds from further development for CNS therapeutics. Moreover, high transporter expression levels that are present in individual patients or may be generally associated作者: ambivalence 時(shí)間: 2025-3-30 18:03
Bahnunterhaltung und Materialienverwaltung,zed and microsized drug carriers have been developed to increase the notoriously low penetration of active agents into the skin, which limits not only the topical therapy of skin disease but also transdermal therapy. Today, liposome- and microsponge-based preparations are approved for dermatomycosis
